CEL-SCI Corporation (CEL-SCI) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 2000.
Business Overview: CEL-SCI is a biopharmaceutical company focused on the research and development of immunotherapies and vaccines. The Company has no commercial products currently generating revenue and relies on equity financing and grants to fund operations. Primary development candidates include MULTIKINE (a cytokine cocktail for cancer), L.E.A.P.S. technology (for vaccines against malaria, herpes, and cancer), and an HIV vaccine (HGP-30).
Key Financial Metrics
| Metric | Fiscal 2000 | Fiscal 1999 | Fiscal 1998 |
|---|---|---|---|
| Total Revenue | $442,551 | $469,518 | $792,994 |
| Net Loss | $(8,478,397) | $(7,490,725) | $(6,442,683) |
| Loss Per Share (Basic/Diluted) | $(0.44) | $(0.52) | $(0.74) |
| Research & Development Expenses | $4,978,714 | $4,461,051 | $3,833,854 |
| General & Administrative Expenses | $3,721,240 | $3,230,982 | $3,106,492 |
| Cash and Cash Equivalents | $6,909,263 | $2,747,644 | $2,813,225 |
| Investment Securities | $3,760,922 | $3,191,491 | $3,191,491 |
| Total Assets | $13,808,882 | $7,559,772 | $14,431,813 |
| Total Liabilities | $847,423 | $461,586 | $456,529 |
| Working Capital | $11,725,940 | $6,152,715 | $12,926,014 |
Note: Revenue consists entirely of investment income and other non-operating income. The Company has no product sales.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $988,000 (13%) compared to fiscal 1999, driven by higher R&D and G&A expenses.
- R&D Expansion: R&D expenses rose by $517,663 (12%) due to the initiation of larger and more numerous clinical trials for MULTIKINE.
- G&A Increase: General and administrative expenses increased by $490,258 (15%), attributed to legal costs associated with a lawsuit brought by former directors (settled in May 2000) and increased staffing.
- Liquidity Improvement: Cash and cash equivalents more than doubled from $2.75 million to $6.91 million, resulting from significant equity financing activities in late 1999 and early 2000.
- Capital Structure: The Company completed private placements of common stock and warrants in December 1999 and March 2000, raising approximately $10.5 million in aggregate proceeds.
Outlook, Risks, and Management Commentary
- Guidance: Management expects to spend approximately $5,000,000 on research, development, and clinical trials during fiscal 2001. The Company plans to fund this using existing resources but acknowledges the need for additional financing for extensive future trials.
- Strategic Focus: The Company is prioritizing MULTIKINE development for head and neck cancer. It has entered an agreement with Orient Europharma for exclusive marketing rights in Taiwan, Singapore, Hong Kong, and Malaysia. The Company has ceased active development of its AIDS vaccine (HGP-30) due to political constraints in target regions, though it seeks licensing partners.
- Regulatory Risks: No products have received FDA approval. Clinical trials have been conducted under state or foreign approvals, which may not be accepted by the FDA. Commercialization is estimated to be several years away.
- Financial Risks: The Company has a history of net losses and no operating revenue. Continued operations are dependent on the ability to raise additional capital through equity or debt financing, which is not guaranteed.
- Unusual Items: A significant portion of G&A expenses in 2000 relates to the settlement of litigation with former directors. Additionally, the Company recorded a stock bonus of $550,000 to an officer in fiscal 2000.
Investor Verification Checklist
- Cash Burn Rate: Verify the sufficiency of the $6.9 million cash balance against the projected $5 million spend for fiscal 2001 and the timeline for future capital raises.
- Regulatory Pathway: Confirm the status of FDA acceptance for clinical data generated in foreign jurisdictions (Israel, Netherlands) and the specific requirements for IND/BLA filing.
- Equity Dilution: Review the terms of outstanding warrants (Series A/B from 1997, private placement warrants from 1999/2000) and their potential impact on share count upon exercise.
- Contractual Obligations: Assess the financial terms of the agreement with Orient Europharma and the royalty obligations to CELL-MED regarding the L.E.A.P.S. technology.
- Related Party Transactions: Note the employment agreements and significant stock ownership of the President (Maximilian de Clara) and CEO (Geert R. Kersten), who are related by family.